Literature DB >> 6307212

Morphometric analysis of differentiation in human breast carcinoma. Tumor heterogeneity.

F E Sharkey.   

Abstract

The assumption that tumor grading is best performed in the region having the least differentiation was tested in a series of mammary ductal carcinomas by quantitating the relative amounts of neoplastic cells that remain within ducts (intraductal tumor [IN]) or participate in glandular formations (differentiated infiltrating tumor [DI]). Field-to-field variation in these two elements displayed a linear correlation with their overall level in each tumor. Since having less than 10% DI + IN is a marker for recurrence among breast cancer patients, this marker was applied to find variant regions of potential biological importance. Such regions were common, but their distribution was random, and they varied so much within themselves that they were not significantly different from the remainder of the tumor. Furthermore, the existence of such poorly differentiated regions did not correlate with a poor prognosis. Grading should be performed on a sample that is representative of the entire tumor, rather than its least differentiated part.

Entities:  

Mesh:

Year:  1983        PMID: 6307212

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  3 in total

1.  Correlation of aromatase activity with histological differentiation of breast cancer--a morphometric analysis.

Authors:  A Lipton; R J Santen; S J Santner; H A Harvey; D White-Hershey; M J Bartholomew; F E Sharkey
Journal:  Breast Cancer Res Treat       Date:  1988-09       Impact factor: 4.872

2.  Do aggressive subclones within primary colorectal cancer give rise to liver metastases?

Authors:  J R Jass; K Mukawa; P I Richman; P A Hall
Journal:  Int J Colorectal Dis       Date:  1989       Impact factor: 2.571

3.  The impact of osteoblastic differentiation on osteosarcomagenesis in the mouse.

Authors:  T Quist; H Jin; J-F Zhu; K Smith-Fry; M R Capecchi; K B Jones
Journal:  Oncogene       Date:  2014-10-27       Impact factor: 9.867

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.